Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation
August 26, 2020
In another victory on behalf of Axinn’s client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy’s Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior’s opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Attorneys Recognized by IAM Patent 1000
News
Intellectual Property
Intellectual Property and Antitrust
Byline Articles
Intellectual Property
Axinn Recognized by Legal 500 2025 U.S. Guide for Excellence in Antitrust and Litigation
Awards & Recognitions
Axinn Earns Band 1 Recognition in Multiple Categories in 2025 Chambers USA Guide
Awards & Recognitions
Antitrust